about
Clinical pharmacology of bivalirudin.Lepirudin use in a neonate with heparin-induced thrombocytopenia.Pharmacotherapy of heparin- induced thrombocytopenia.Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction.Limitations of traditional anticoagulants.Minimising the risk of heparin-induced osteoporosis during pregnancy.Treatment of heparin-induced thrombocytopenia with drotrecogin alfa (activated).Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approach.Heparin-induced thrombocytopenia: treatment options and special considerations.Severe anaphylactic reaction after repeated intermittent exposure to lepirudin.Fondaparinux as a treatment option for heparin-induced thrombocytopenia.Successful use of argatroban during the third trimester of pregnancy: case report and review of the literature.Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia.The Pharmacotherapy of Heparin-Induced Thrombocytopenia (HIT) : A Review of Contemporary Therapeutic Challenges in Clinical Practice.Bleeding risk factors associated with argatroban therapy in the critically ill.Effect of lepirudin on the international normalized ratio.Prophylaxis and treatment of venous thromboembolism in the critically ill.Comment: treatment of heparin-induced thrombocytopenia.Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice.Acquired Thrombophilia.
P2860
Q33342833-98379243-540D-47CB-B8C8-BF959C8BD266Q33346256-D38E4FEC-20D5-49B1-952D-B012AC799F97Q33348283-7523C603-A6CE-49E5-B6EB-201E24BEFF08Q33360104-25D45DBE-869D-43B2-9BDF-12E7069E14ACQ33362181-8A143E17-3F10-43C4-965B-B904DE667EDAQ33366632-5BD276C0-FA77-475F-A479-FE20BE6D010DQ33370372-F0C009B7-D721-4D94-B1AC-A7B2BA19160FQ33372266-25A1F326-8FF4-45A1-A347-757A8795BBF3Q33374658-541F12A9-3EA6-4BBD-88A4-8A289660BA8DQ33375021-916144DC-D25F-4F8A-8B1C-499DAA9E6BFBQ33375448-74E6FA64-9F5E-45A7-BF4D-8499E6481DDAQ33382099-858A2876-18BF-4147-B9C4-118A86FC0887Q33385898-39B4FE96-B6F4-45E5-B458-9F08D923543FQ33401236-4A00A85B-65A1-4763-BC8B-6BC141C2B188Q33402036-2AF2DFE5-1898-4502-BF5D-39F534540464Q35980239-B337BFAA-1A23-4639-9AF1-43C466040473Q38130269-369ADF08-8A2F-4DC1-8442-300F003E51BEQ44114560-1D27A087-8624-4D8B-880E-D94721ADA6B5Q51677840-DF60B794-5CF6-4477-BD66-E57AD2A78B08Q51846266-A8540DE7-D8AE-4606-86D4-080AD76C5BE5
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Treatment of heparin-induced thrombocytopenia.
@ast
Treatment of heparin-induced thrombocytopenia.
@en
type
label
Treatment of heparin-induced thrombocytopenia.
@ast
Treatment of heparin-induced thrombocytopenia.
@en
prefLabel
Treatment of heparin-induced thrombocytopenia.
@ast
Treatment of heparin-induced thrombocytopenia.
@en
P2860
P356
P1476
Treatment of heparin-induced thrombocytopenia.
@en
P2093
Richard H White
William E Dager
P2860
P304
P356
10.1345/APH.1A204
P407
P577
2002-03-01T00:00:00Z